Sari Khaleel(@sari_safaa) 's Twitter Profileg
Sari Khaleel

@sari_safaa

Urologic Oncologist.

ID:180462367

calendar_today19-08-2010 18:01:32

443 Tweets

102 Followers

66 Following

Dr. Glaucomflecken(@DGlaucomflecken) 's Twitter Profile Photo

I’m seeing some “free market” simps defending Nature’s 12k open access fees. Guess it’s time to bring this back around.

account_circle
Ashish M. Kamat, MD, MBBS(@UroDocAsh) 's Twitter Profile Photo

En bloc TURBT (for <1 cm tumors) results in

Similar recurrence rates: 18.4% vs 16.7% at 1 yr

Similar residual disease on reTUR 56% vs 55.9% (small subset)

More retrieval of DM: 80.7% vs 71.1%

Less bladder perforation: 5.6% vs 12%

Similar OR time: 26 vs 25 min

account_circle
Andrew Nguyen(@AndrewNguyenUro) 's Twitter Profile Photo

'Your doctor ordered a CT scan... it is not medically necessary to use this test... there are other tests such as... a CT scan of the abdomen, that might help.'

'Your doctor ordered a CT scan... it is not medically necessary to use this test... there are other tests such as... a CT scan of the abdomen, that might help.'
account_circle
Hong Truong(@HongTruongMD) 's Twitter Profile Photo

Dr. Laudone is a phenomenal role model, teacher, and mentor. “Teacher of the Year” may be an understatement.

account_circle
Mueller, She Wrote(@MuellerSheWrote) 's Twitter Profile Photo

THREAD: A STORY: When I was working for the Department of Veterans Affairs as the supervisor of the San Diego VA Health System Call Center as a GS-9, I wanted to create a monthly customer service award. Kind of like an “employee of the month”. 1/

account_circle
Behfar Ehdaie(@BehfarEhdaieMD) 's Twitter Profile Photo

UrologyMSK Eur Urol Focus marlon perera Ghalib Jibara Sigrid Carlsson James Eastham Vincent Laudone Karim Touijer Study lead by UroOnc fellows: Dr Perera and Dr Jibara. This study builds on prior data evaluating the impact of re-grading based on MR/biopsy (comfirmatory bx) on clinical outcomes. More evidence that if a cancer is hard to find, then it is probably less aggressive…

account_circle
Dr. Glaucomflecken(@DGlaucomflecken) 's Twitter Profile Photo

I think health insurance companies come up with all these names to obscure the fact that they own US healthcare. Optum is owned by United, CVS is Aetna, express scripts is Cigna. They are all vertically integrating & gouging patients/independent pharmacies for insane profits.

account_circle
Chris Filson(@chrisfilson_uro) 's Twitter Profile Photo

Amazing how Epic EMR unveils a window into surgical costs at the hospital level

First observation - robotic single port RALP has absurdly higher case costs than multiport, lol

account_circle
Nicholas Zaorsky, MD MS(@NicholasZaorsky) 's Twitter Profile Photo

If Darth Vader had to make a commercial about why the Death Star was great and would solve many problems, it would look like this EviCore By Evernorth ad.

account_circle
Bryan Carmody(@jbcarmody) 's Twitter Profile Photo

WSJ covered resident unions today.

Article dropped 3h ago; 400+ comments already.

My fave is “There was no issue with work-life balance until women became MDs!”

But don’t worry, Stockholm syndrome, the bootstraps brigade, and socialized medicine fearmongering are there, too.

WSJ covered resident unions today. Article dropped 3h ago; 400+ comments already. My fave is “There was no issue with work-life balance until women became MDs!” But don’t worry, Stockholm syndrome, the bootstraps brigade, and socialized medicine fearmongering are there, too.
account_circle
Mark Tyson(@MarkTysonMD) 's Twitter Profile Photo

Results from neoadj UTUC trial led by JonathanColeman. Split dose cis-based NAC led to 19% pathCR rate. Have seen this in practice, with some choosing switch maintenance in lieu of neph-u to avoid dialysis. Great study, adds to EA8141 and POUT. ascopubs.org/doi/10.1200/JC…

Results from neoadj UTUC trial led by JonathanColeman. Split dose cis-based NAC led to 19% pathCR rate. Have seen this in practice, with some choosing switch maintenance in lieu of neph-u to avoid dialysis. Great study, adds to EA8141 and POUT. ascopubs.org/doi/10.1200/JC…
account_circle
Chung-Han Lee 李宗翰, MD/PhD(@ChungHanLee3) 's Twitter Profile Photo

Pramod John (CEO) Dr. Thomas Morrow (CSO) of Vivio Health just been denied a treatment in a Peer-to-Peer of a NCCN preferred regimen for RCC, and told that your team of 4 oncologists knows how to read clinical trials better than NCCN and the RCC group at Memorial Sloan Kettering Cancer Center

account_circle